妊娠期妇科癌症的管理:多学科共识解读
妊娠期癌症发生率约为1/1000,需多学科团队协作。本文基于综述汇总妊娠期妇科癌症的诊疗要点,强调个体化延迟治疗、手术时机选择及化疗限制,指出妊娠不改变妇科恶性肿瘤的侵袭行为或预后。
要点
- 妊娠期宫颈癌可考虑延迟治疗,但晚期患者需立即放化疗。
- 附件包块多数良性,持续者手术宜在15-20周,优先腹腔镜。
- 化疗应在器官形成后且孕34周前进行,避免新生儿骨髓抑制。
核心结论
- 妊娠期妇科恶性肿瘤的临床行为及预后与非妊娠期相似。
- 多学科共识团队应包括妇科肿瘤、病理、新生儿、放射、麻醉、母胎医学及社工。
研究设计与样本
- 本文为综述,汇总妊娠期妇科癌症的诊断与管理证据。
主要发现
- 妊娠期癌症发生率为1/1000妊娠。
- 多数附件包块为良性且在孕中期消退。
- 妊娠期可安全进行超声和磁共振成像评估。
- 化疗可在孕中晚期器官形成后给予,但孕34周后应停止。
- 抗血管生成药物、免疫检查点抑制剂和PARP抑制剂应避免整个孕期使用。
关键数值与推荐
- 早期宫颈癌可 deliberate 延迟治疗,但存在肉眼病灶时禁忌阴道分娩。
- 剖宫产时推荐行根治性子宫切除术加淋巴结清扫。
- 局部晚期和转移/复发性疾病应分别立即开始放化疗和全身治疗。
- 持续性无症状良性外观附件包块可保守管理;手术宜在15-20周进行。
- 良性、恶性生殖细胞肿瘤及交界性肿瘤行单侧附件切除,保留子宫和对侧卵巢。
临床怎么用
- 妊娠期宫颈癌筛查应持续推进,早期病例可考虑延迟治疗。
- 附件包块手术时机选择孕15-20周,优先腹腔镜。
- 需化疗者应在孕中晚期进行,孕34周后停止以避免新生儿骨髓抑制。
- 避免孕期使用贝伐珠单抗、免疫检查点抑制剂和PARP抑制剂。
局限性
- 本文为综述,未报告系统检索策略及证据等级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer complicates 1 in 1000 pregnancies. Multidisciplinary consensus comprised of Gynecologic Oncology, Pathology, Neonatology, Radiology, Anesthesiology, Maternal Fetal Medicine, and Social Work should be convened. Pregnancy provides an opportunity for cervical cancer screening, with deliberate delays in treatment permissible for early stage carcinoma. Vaginal delivery is contraindicated in the presence of gross lesion(s) and radical hysterectomy with lymphadenectomy at cesarean delivery is recommended. Women with locally advanced and metastatic/recurrent disease should commence treatment at diagnosis with chemoradiation and systemic therapy, respectively; neoadjuvant chemotherapy to permit gestational advancement may be considered in select cases. Most adnexal masses are benign and resolve by the second trimester. Persistent, asymptomatic, benign-appearing masses can be managed conservatively; surgery, if indicated, is best deferred to 15-20 weeks, with laparoscopy preferable over laparotomy whenever possible. Benign and malignant germ cell tumors and borderline tumors are occasionally encountered, with unilateral adnexectomy and preservation of the uterus and contralateral ovary being the rule. Epithelial ovarian cancer is exceedingly rare. Ultrasonography and magnetic resonance imaging lack ionizing radiation and can be employed to evaluate disease extent. Tumor markers, including CA-125, AFP, LDH, inhibin-B, and even CEA and ßhCG may be informative. If required, chemotherapy can be administered following organogenesis during the second and third trimesters. Because platinum and other anti-neoplastic agents cross the placenta, chemotherapy should be withheld after 34 weeks to avoid neonatal myelosuppression. Bevacizumab, immune checkpoint inhibitors, and PARP inhibitors should be avoided throughout pregnancy. Although antenatal glucocorticoids to facilitate fetal pulmonary maturation and amniotic fluid index assessment can be considered, there is no demonstrable benefit of tocolytics, antepartum fetal heart rate monitoring, and/or amniocentesis. Endometrial, vulvar, and vaginal cancer in pregnancy are curiosities, although leiomyosarcoma and the dreaded twin fetus/hydatidiform mole have been reported. For gynecologic malignancies, pregnancy does not impart aggressive clinical behavior and/or worse prognosis.
引用
- Korenaga TK, Tewari KS. Gynecologic cancer in pregnancy. Gynecol Oncol. 2020. PMID: 32268951. doi:10.1016/j.ygyno.2020.03.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。